Sirtris, Novel Endogenous SIRT1 Activator

Nov. 9, 2007--... The natural SIRT1 activator, AROS, and Sirtris' proprietary SIRT1 activators both bind to the N-terminus of SIRT1. This further validates SRT501, and more potent Sirtris new chemical entities that are up to 1000 times more potent than SRT501, as potential drug targets for diseases of aging including metabolic disorders such as Type 2 Diabetes, mitochondrial disorders such as MELAS, neurological disorders, and cancer.... Sirtris Press Release -